Please assess the completion status of the following clinical trial:

Trial Title: Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has a histologically confirmed diagnosis of breast cancer documented by cytology or biopsy.~* Has evidence of metastatic breast cancer with a minimum of one lesion per Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v 1.1) criteria.~* Is receiving a chemotherapy regimen including one of the following: anthracycline, taxane, gemcitabine, vinorelbine or capecitabine.~* Has planned treatment with the same chemotherapy regimen for a minimum of 9 weeks after Day 1 of study intervention administration.~* ≥ 30 days elapsed (from Day 1) since previous treatment with an erythropoiesis stimulating agent (ESA) (including treatment with intravenous (IV) iron) for chemotherapy induced anemia.~* ≥ 7 days elapsed (from Day 1) since the last red blood cell (RBC) transfusion and receipt of ≤ 2 units of blood in the past 30 days.~* Life expectancy of ≥ 6 months.~Exclusion Criteria:~* Has had prior radiation therapy to \> 20% of the whole skeleton.~* Has had \> 5 prior chemotherapy treatment regimens for metastatic breast cancer.~* Has a history of autoimmune or hereditary hemolysis or gastrointestinal bleeding.~* Has clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or genitourinary disease unrelated to underlying hematologic disorder.~* Has heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher.~* Has a recent history of thrombosis, deep vein thrombosis (DVT), pulmonary emboli, or embolic stroke, occurring within the last 6 months.~* Has untreated central nervous system (CNS) metastases or CNS metastases treated with whole brain radiotherapy \< 6 months prior to Day 1.~* Has a diagnosis of a myeloid malignancy or known history of myelodysplasia.~* Has a history of second malignancy within 5 years (except excised and cured basal cell carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).~* Has had administration of IV antibiotics or febrile (temperature elevation \> 38 ° C) within 14 days of Day 1.~* Has uncontrolled hypertension.~* Has known history of hepatitis B surface antigen (HBsAg and HB core antibody (Ab)), human immunodeficiency virus (HIV) antibody or active hepatitis C.~* Has clinically significant iron (transferrin saturation \< 20%), vitamin B12, or folate deficiency.~* Has a history of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or thalassemia.~* Has a history of autoimmune or hereditary hemolysis; active gastrointestinal bleeding (within the last 6 months as compared to Day 1).~* Has received treatment with another investigational drug or device within 1 month prior to Day 1.~* Is pregnant or lactating.~* Has a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product.~* Has had major surgery within 30 days prior to Day 1 (patients must have completely recovered from any previous surgery prior to Day 1).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sotatercept 0.1 mg/kg (Type: EXPERIMENTAL): Participants will receive sotatercept 0.1 mg/kg subcutaneously every 28 days up to 4 doses.
- Sotatercept 0.3 mg/kg (Type: EXPERIMENTAL): Participants will receive sotatercept 0.3 mg/kg subcutaneously every 28 days up to 4 doses.
- Sotatercept 0.5 mg/kg (Type: EXPERIMENTAL): Participants will receive sotatercept 0.5 mg/kg subcutaneously every 28 days up to 4 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo subcutaneously every 28 days up to 4 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).